Table 1.
Clinical and laboratory features of enrolled patients divided according to seroconversion status for anti-Spike antibodies.
| All patients N = 149 |
Seroconverted N = 135 |
Not seroconverted N = 14 |
|
|---|---|---|---|
| Age, years | 73 (17–93) | 73 (17–93) | 75 (50–86) |
| Males/females | 79/70 | 73/62 | 6/8 |
| Disease | |||
| Warm AIHA, N (%) | 21 | 15 (71) | 6 (29)* |
| Cold AIHA, N (%) | 16 | 14 (88) | 2 (12) |
| ITP, N (%) | 25 | 24 (96) | 1 (4) |
| Evans syndrome, N (%) | 11 | 7 (64) | 4 (36)* |
| AA, N (%) | 11 | 11 (100) | 0 (0) |
| PNH, N (%) | 19 | 19 (100) | 0 (0) |
| LR-MDS, N (%) | 46 | 45 (98) | 1 (2) |
| Laboratory values | |||
| Neutrophils ×109/L | 3.1 (0.07–16) | 3.07 (0.07–16) | 3.6 (0.2–14) |
| Lymphocytes ×109/L | 1.53 (0.37–5.8) | 1.5 (0.37–5.8) | 1.3 (0.51–5.2) |
| Total IgG, mg/dL | 951 (207–2128) | 998 (207–2128) | 659 (256–1011)** |
| Therapy | |||
| No treatment, N (%) | 41 | 38 (93) | 3 (7) |
| Steroids, N (%) | 31 | 24 (77) | 7 (23)*** |
| Dose, mg/day | 7.5 (3–62.5) | 7.5 (2.5–37.5) | 10 (5–62.5) |
| Cyclosporine, N (%) | 19 | 19 (100) | 0 (0) |
| Complement inhibitor, N (%) | 20 | 20 (100) | 0 (0) |
| Combined immunosuppressants, N (%) | 10 | 8 (80) | 2 (20)*** |
| BM stimulating agents, N (%) | 28 | 26 (93) | 2 (7) |
| < 12 months from rituximab | 5 | 2 (40) | 3 (60)*** |
| Time from rituximab, months | 24 (1–156) | 26 (6–156) | 21 (1–72) |
| Previous COVID-19, N(%) | 18 | 18 (100) | 0 (0)* |
*p ≤ 0.001; **p = 0.005; ***p < 0.05.